Authors:
Bunworasate, U
Arnouk, H
Minderman, H
O'Loughlin, KL
Sait, SNJ
Barcos, M
Stewart, CC
Baer, MR
Citation: U. Bunworasate et al., Erythropoietin-dependent transformation of myelodysplastic syndrome to acute monoblastic leukemia, BLOOD, 98(12), 2001, pp. 3492-3494
Authors:
Minderman, H
Wrzosek, C
Cao, SS
Utsugi, T
Kobunai, T
Yamada, Y
Rustum, YM
Citation: H. Minderman et al., Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells, CANC CHEMOT, 45(1), 2000, pp. 78-84
Authors:
Slocum, HK
Parsons, JC
Winslow, EO
Broderick, L
Minderman, H
Toth, K
Greco, WR
Rustum, YM
Citation: Hk. Slocum et al., Time-lapse video reveals immediate heterogeneity and heritable damage among human ileocecal carcinoma HCT-8 cells treated with raltitrexed (ZD1694), CYTOMETRY, 41(4), 2000, pp. 252-260
Authors:
Yin, MB
Guo, B
Vanhoefer, U
Azrak, RG
Minderman, H
Frank, C
Wrzosek, C
Slocum, HK
Rustum, YMN
Citation: Mb. Yin et al., Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a noveltopoisomerase I inhibitor BNP1350, MOLEC PHARM, 57(3), 2000, pp. 453-459
Authors:
Voigt, W
Matsui, S
Yin, MB
Burhans, WC
Minderman, H
Rustum, YM
Citation: W. Voigt et al., Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis, ANTICANC R, 18(5A), 1998, pp. 3499-3505